IV treatment is one of the most traditionalist and wide-spread treatments provided to the 90% of hospitalised patients, yet, recent supply challenges like the Baxter IV fluids crisis have shown that ...
AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback